Ajay Nirula, M.D., Ph.D., was promoted to president while retaining his role as head of research and development1
Catherine Bovenizer, C.P.A., was named chief financial officer, transitioning from senior vice president of finance and business operations1
The promotions followed major accomplishments including dosing of the oral STAT6 inhibitor REX-8756 in its first clinical study and securing a financing round with institutional and strategic investors1
Nancy Whiting, Pharm.D., serves as president and chief executive officer of Recludix1
Prior to his promotion, Dr. Nirula was senior vice president and immunology therapeutic head for Eli Lilly and Company and served as site head for Lilly Biotechnology Center in San Diego1
Recludix is a clinical-stage company focused on discovering and developing inhibitors for inflammatory disease1
Sources:
1. https://www.biospace.com/press-releases/recludix-pharma-promotes-executive-leaders-following-recent-corporate-accomplishments